These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26063886)

  • 21. Practice protocol for the examination of specimens removed from patients with carcinoma of the urinary bladder, ureter, renal pelvis, and urethra.
    Hammond EH; Henson DE; ;
    Arch Pathol Lab Med; 1996 Dec; 120(12):1103-10. PubMed ID: 15456174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline.
    Stratigos A; Garbe C; Lebbe C; Malvehy J; del Marmol V; Pehamberger H; Peris K; Becker JC; Zalaudek I; Saiag P; Middleton MR; Bastholt L; Testori A; Grob JJ; ; ;
    Eur J Cancer; 2015 Sep; 51(14):1989-2007. PubMed ID: 26219687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pure and predominantly pure intralymphatic breast carcinoma after neoadjuvant chemotherapy: an unusual and adverse pattern of residual disease.
    Rabban JT; Glidden D; Kwan ML; Chen YY
    Am J Surg Pathol; 2009 Feb; 33(2):256-63. PubMed ID: 18936689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Society of Gynecologic Oncologists (SGO) ovarian cancer quality surgical measures.
    Gogoi RP; Urban R; Sun H; Goff B
    Gynecol Oncol; 2012 Aug; 126(2):217-9. PubMed ID: 22561039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathology after neoadjuvant treatment - How to assess residual disease.
    Viale G; Fusco N
    Breast; 2022 Mar; 62 Suppl 1(Suppl 1):S25-S28. PubMed ID: 34810049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer?
    Perez RO; Habr-Gama A; Pereira GV; Lynn PB; Alves PA; Proscurshim I; Rawet V; Gama-Rodrigues J
    Colorectal Dis; 2012 Jun; 14(6):714-20. PubMed ID: 22568644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics.
    Nagao T; Kinoshita T; Hojo T; Tsuda H; Tamura K; Fujiwara Y
    Breast; 2012 Jun; 21(3):289-95. PubMed ID: 22277312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How do we measure a residual tumor size in histopathology (the gold standard) after neoadjuvant chemotherapy?
    Apple SK; Suthar F
    Breast; 2006 Jun; 15(3):370-6. PubMed ID: 16185870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting.
    Sahoo S; Lester SC
    Arch Pathol Lab Med; 2009 Apr; 133(4):633-42. PubMed ID: 19391665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
    Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
    Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
    Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
    Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intralaboratory timeliness of surgical pathology reports. Results of two College of American Pathologists Q-Probes studies of biopsies and complex specimens.
    Zarbo RJ; Gephardt GN; Howanitz PJ
    Arch Pathol Lab Med; 1996 Mar; 120(3):234-44. PubMed ID: 8629897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pentameric last-digit preference and stage border avoidance in pathology measurement.
    den Bakker MA; Damhuis RAM
    Histopathology; 2018 Sep; 73(3):510-513. PubMed ID: 29701881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathology is a necessary and informative tool in oncology clinical trials.
    Nagtegaal ID; West NP; van Krieken JH; Quirke P
    J Pathol; 2014 Jan; 232(2):185-9. PubMed ID: 24037805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Standardization of pathologic complete response rates in breast cancer treatment.
    Knauer M; Devries A; Wenzl E; Haid A
    Breast Cancer Res Treat; 2008 Jul; 110(2):395-6. PubMed ID: 17851755
    [No Abstract]   [Full Text] [Related]  

  • 36. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
    Mombelli S; Kwiatkowski F; Abrial C; Wang-Lopez Q; de Boissieu P; Garbar C; Bensussan A; Curé H
    Oncology; 2015; 88(5):261-72. PubMed ID: 25573741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Standards, options and recommendations for the composition of anatomic and surgical pathology reports or cytopathology reports in oncology].
    Arnould L; Fiche M; Blanc-Vincent MP; Le Doussal V; Signal-Zafrani B; Gory-Delaboere G; Briffod M; Vielh P; Voigt JJ;
    Ann Pathol; 2003 Feb; 23(1):79-95. PubMed ID: 12743509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Bossuyt V; Provenzano E; Symmans WF; Webster F; Allison KH; Dang C; Gobbi H; Kulka J; Lakhani SR; Moriya T; Quinn CM; Sapino A; Schnitt S; Sibbering DM; Slodkowska E; Yang W; Tan PH; Ellis I
    Histopathology; 2024 Jun; 84(7):1111-1129. PubMed ID: 38443320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology.
    Li X; Oprea-Ilies GM; Krishnamurti U
    Arch Pathol Lab Med; 2017 Apr; 141(4):490-498. PubMed ID: 28353377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis.
    Lopez-Beltran A; Bassi P; Pavone-Macaluso M; Montironi R
    Eur Urol; 2004 Mar; 45(3):257-66. PubMed ID: 15036668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.